Common Blood Thinner May Be Linked to Slower Mental Decline in Alzheimer’s Patients

For millions of Americans living with Alzheimer’s disease, slowing memory loss is the central hope of modern medicine. A large new study from Sweden points to an unexpected ally in that fight: a type of blood thinner already used by many older adults to prevent strokes.

Researchers found that Alzheimer’s patients who also had atrial fibrillation, a common irregular heartbeat condition, experienced modestly slower mental decline when taking newer blood thinners called NOACs compared to patients taking older-style blood thinners or no blood thinners at all. Atrial fibrillation affects nearly one in five people at the time of a dementia diagnosis, making this overlap far more common than many people realize.

Published in the European Heart Journal, the analysis drew on data from more than 7,000 patients in a Swedish national health database.

Who Was Studied and How

Researchers pulled records from a Swedish national dementia registry, identifying patients diagnosed with Alzheimer’s disease between May 2007 and December 2020 who also had a documented history of atrial fibrillation. After filtering out those who didn’t meet the study criteria, 7,308 people were included in the final analysis.

Participants were divided into three groups based on what blood thinner, if any, they were taking at the time of their Alzheimer’s diagnosis: 3,341 were taking no blood thinner, 2,277 were on warfarin, the older traditional option, and 1,690 were on a NOAC, the newer class. The average age at diagnosis was 82.6 years, and slightly more than half of participants were women.

Memory and thinking ability were tracked using a standard test called the Mini-Mental State Examination, or MMSE, which gives patients a score based on their mental function. Scores were recorded at diagnosis and then at follow-up visits over five years. Researchers also tracked strokes, major bleeding episodes, bone fractures, and deaths. The primary clinical comparisons focused on outcomes over three years, with additional analyses extending to five years.

To make the comparison as fair as possible, the team used a statistical method to account for the fact that patients in different groups likely had different health profiles to begin with. Patients who weren’t taking any blood thinner tended to be slightly older and had lower initial memory scores, which makes sense given that doctors may have been more cautious about prescribing these medications to frailer patients.

What the Numbers Show About Blood Thinners and Memory

At the start of the study, all three groups had roughly similar memory scores, averaging around 21.5 points. Five years later, the gap between groups had grown. Non-users of blood thinners scored an estimated 14.3 points on average, warfarin users scored about 14.5, and NOAC users scored approximately 15.3. While these differences might look small, the researchers note that the estimated slowdown in memory decline, roughly 0.23 points per year compared to non-users and roughly 0.21 points per year compared to warfarin users, sits in a similar range to the effect seen with some commonly used Alzheimer’s drugs, such as cholinesterase inhibitors. The paper offers that comparison as context, not as the result of a direct head-to-head trial.

On the clinical side, NOACs showed clear advantages. Compared to taking no blood thinner, NOAC use was associated with a 19% lower risk of death, a 34% lower risk of stroke or systemic embolism, and a 21% lower risk of bone fractures. Warfarin also reduced stroke risk and death rates compared with people not taking anticoagulants, but warfarin users faced a 31% higher risk of major bleeding events, a serious concern for elderly patients.

When researchers compared NOACs directly to warfarin, NOACs came out ahead on stroke prevention, a statistically significant edge. Point estimates for major bleeding, death, and fractures also leaned in favor of NOACs, though those differences were smaller and did not reach statistical significance in the head-to-head comparison.

Why Blood Thinners Might Be Linked to Better Brain Outcomes in Alzheimer’s Patients

Study authors point to several reasons why blood thinners, and NOACs in particular, may benefit the brain beyond just preventing strokes. Preventing clots can reduce both obvious strokes and smaller, “silent” brain injuries that chip away at memory over time. Laboratory research also connects the biological machinery of blood clotting to Alzheimer’s disease itself. A protein closely associated with Alzheimer’s, called amyloid-beta, has been shown in lab studies to interact with the clotting system in ways that may worsen the disease. Experimental studies in animals have suggested that normalizing the clotting system may slow Alzheimer’s progression, though this has not yet been proven in people.

Researchers also noted that warfarin’s more complicated management, requiring regular blood tests and careful dosing, may make it harder for people with memory problems to use safely and consistently. Warfarin users in the study more often drifted from their prescribed treatment, such as switching or stopping the drug, than NOAC users. The study authors suggest that this gap in real-world use may partly explain why NOACs performed better.

This study was observational, meaning it tracked what happened to patients in the real world rather than randomly assigning people to different treatments. So it cannot definitively prove that NOACs cause slower memory decline. Patients who were prescribed NOACs may have differed from other groups in ways the researchers couldn’t fully measure, such as overall frailty, family support, or how closely they followed medical advice. Because most patients with atrial fibrillation had already started blood thinners before their Alzheimer’s diagnosis, the study reflects the effects of continuing these medications rather than starting them fresh.

Researchers were also clear that while these results are encouraging, decisions about blood thinners in Alzheimer’s patients should still be driven primarily by stroke prevention rather than any anticipated benefit for memory. For patients who live with both conditions, that guidance matters: in this population, the treatment tied to better protection against clots was also the one tied to slower cognitive decline.

Disclaimer: This article summarizes findings from a single observational study and is for general informational purposes only. It is not medical advice. Observational research can show associations but cannot prove that one thing causes another. Do not start, stop, or change any medication, including blood thinners, based on this article. Anyone with questions about anticoagulants, atrial fibrillation, or Alzheimer’s disease should consult a qualified healthcare provider who knows their individual medical history.

---